Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors.
Pou Hong Justin Chia *Azrieli Centre for Neuro-Radiochemistry, Brain Health Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON M5T 1R8, Canada.
Takuya Toyonaga *Department of Radiology and Biomedical Imaging, Yale School of Medicine, Yale University, New Haven, CT 06520.ORCID 0000-0002-0369-8294
Junchao TongAzrieli Centre for Neuro-Radiochemistry, Brain Health Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON M5T 1R8, Canada.ORCID 0000-0001-9299-0045
Hannah LeAzrieli Centre for Neuro-Radiochemistry, Brain Health Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON M5T 1R8, Canada.
Mark DiasDepartment of Radiology and Biomedical Imaging, Yale School of Medicine, Yale University, New Haven, CT 06520.
Amanda J BoyleAzrieli Centre for Neuro-Radiochemistry, Brain Health Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON M5T 1R8, Canada.ORCID 0000-0001-5588-3507
Roger RaymondAzrieli Centre for Neuro-Radiochemistry, Brain Health Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON M5T 1R8, Canada.
Erin E LongbrakeDepartment of Neurology, Yale School of Medicine, Yale University, New Haven, CT 06520.
Yiyun HuangDepartment of Radiology and Biomedical Imaging, Yale School of Medicine, Yale University, New Haven, CT 06520.ORCID 0000-0002-6757-3220
Richard E CarsonDepartment of Radiology and Biomedical Imaging, Yale School of Medicine, Yale University, New Haven, CT 06520.ORCID 0000-0002-9338-7966
Laura AirasNeurocenter, Turku University Hospital, University of Turku, Turku 20521, Finland.
Neil VasdevAzrieli Centre for Neuro-Radiochemistry, Brain Health Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON M5T 1R8, Canada.ORCID 0000-0002-2087-5125
Ming-Kai ChenDepartment of Radiology and Biomedical Imaging, Yale School of Medicine, Yale University, New Haven, CT 06520.ORCID 0000-0003-2655-4178
Chao ZhengAzrieli Centre for Neuro-Radiochemistry, Brain Health Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON M5T 1R8, Canada.ORCID 0000-0002-2179-8096
Funding
Canadian Institutes of Health Research (CIHR) CIHR507113Michael J. Fox Foundation for Parkinson's Research (MJFF) MJFF-007878
6 · The paper itself
Abstract
Synaptic loss is increasingly recognized as a key pathological feature in multiple sclerosis (MS), contributing to disease progression and cognitive dysfunction. Synaptic vesicle glycoprotein 2A (SV2A) positron emission tomography (PET) imaging has emerged as a promising tool for quantifying synaptic density in vivo. Here, we used the clinically translatable tracer [
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
SV2A PET reveals synaptic density loss in experimental autoimmune encephalomyelitis and in a pilot multiple sclerosis study. · full record | OpenQuestion